Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Rises By 5.6%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 4,340,000 shares, an increase of 5.6% from the October 15th total of 4,110,000 shares. Approximately 7.9% of the company’s stock are sold short. Based on an average daily volume of 524,700 shares, the short-interest ratio is currently 8.3 days.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $53.78 on Monday. The stock has a market cap of $3.07 billion, a PE ratio of 4.73 and a beta of 0.75. Agios Pharmaceuticals has a 1 year low of $20.96 and a 1 year high of $62.58. The firm has a fifty day moving average price of $46.44 and a 200-day moving average price of $43.94.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Raymond James restated an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $60.00 to $56.00 in a research report on Friday, September 27th. Leerink Partnrs downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $52.33.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.93% of the stock is owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in shares of Agios Pharmaceuticals by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock worth $60,326,000 after purchasing an additional 6,101 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its stake in Agios Pharmaceuticals by 19.7% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock worth $46,392,000 after purchasing an additional 172,180 shares during the period. XTX Topco Ltd grew its holdings in Agios Pharmaceuticals by 56.2% during the 3rd quarter. XTX Topco Ltd now owns 8,329 shares of the biopharmaceutical company’s stock valued at $370,000 after buying an additional 2,996 shares in the last quarter. State Street Corp raised its position in shares of Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after buying an additional 216,484 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new position in shares of Agios Pharmaceuticals in the third quarter worth $97,199,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.